## 1 Associations between vitamin D and autoimmune diseases: Mendelian randomization analysis

- 2 Sizheng Steven Zhao MD PhD<sup>1</sup>, Amy Mason PhD<sup>2,3,4</sup>, Eva Gjekmarkaj<sup>4</sup>, Haruyuki Yanaoka MD<sup>5</sup>,
- 3 Stephen Burgess PhD<sup>2, 3, 4</sup>
- 4
- 5 Affiliations
- 6 1 Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Science,
- 7 School of Biological Sciences, Faculty of Biological Medicine and Health, The University of
- 8 Manchester, Manchester Academic Health Science Centre, Manchester, UK
- 9 2 British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and
- 10 Primary Care, University of Cambridge, Cambridge, UK
- 11 3 Heart and Lung Research Institute, University of Cambridge, Cambridge UK
- 12 4 Medical Research Council Biostatistics Unit, University of Cambridge, Cambridge, UK
- 13 5 Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.

14

- 15 Correspondence to: Dr Stephen Burgess, MRC Biostatistics Unit, East Forvie Building, University of
- 16 Cambridge, Cambridge CB2 OSR, UK. sb452@medschl.cam.ac.uk

17

#### 1 ABSTRACT

- 2 **Objective.** The VITAL trial of vitamin D supplementation suggested a possible protective effect for
- 3 autoimmune diseases but uncertainties remain. We investigated potential causal effects of vitamin
- 4 D on composite and individual autoimmune diseases using Mendelian randomization.
- 5 Methods. We used data from 332,984 participants of the UK Biobank of whom 23,089 had at least
- 6 one autoimmune disease defined using ICD code and/or self-report. Diseases were further
- 7 considered in mechanistic subgroups driven by "autoimmunity" (n=12,774) or "autoinflammation"
- 8 (n=11,164), then individually. We selected variants within gene regions implicated in vitamin D
- 9 biology to generate a weighted genetic score. We performed population-wide analysis using the
- 10 ratio method, then examined non-linear effects across five quantiles based on 25-
- 11 hydroxycholecalciferol levels.
- 12 **Results.** Genetically-predicted vitamin D was associated with lower risk of diseases in the
- 13 autoinflammation group (OR 0.95 per 10ng/ml increase in 25-hydroxycholecalciferol; 95%Cl 0.91-
- 14 0.99; p=0.03) but not the autoimmunity group (OR 0.99; 95%Cl 0.95-1.03; p=0.64) or combined.
- 15 When considering individual diseases, genetically-predicted vitamin D was associated with lower risk
- of psoriasis (OR 0.91; 95%CI 0.85-0.97; p=0.005), the most common disease in the autoinflammation
- 17 group, and suggestively with systemic lupus erythematosus (OR 0.84; 95%CI 0.69-1.02; p=0.08);
- 18 results were replicated using data from independent studies. We found no evidence for a plausible
- 19 non-linear relationship between vitamin D and any outcome.
- 20 **Conclusions.** We found genetic evidence to support a causal link between 25-hydroxycholecalciferol
- 21 concentrations and psoriasis and systemic lupus erythematosus. These results have implications for
- 22 potential disease prevention strategies, and the interpretation and design of vitamin D
- 23 supplementation trials.
- 24
- 25 Keywords: vitamin D, autoimmune disease, autoinflammation, psoriasis, systemic lupus
- 26 erythematosus, genetic instrumental variable, UK Biobank
- 27

## 1 INTRODUCTION

2 Autoimmune diseases are a heterogenous group of conditions that are among the leading causes of 3 life-changing morbidity and even mortality [1,2]. Pharmacological therapies that target the immune 4 system are not always effective and can have prohibitive adverse effects. Vitamin D is highly popular 5 as a complementary and alternative medicine. Enthusiasm for it as a potentially disease modifying 6 agent has largely been driven by pre-clinical studies and a host of observational associations that are 7 at risk of bias from confounding (e.g., factors such as lifestyle and diet that influence both vitamin D 8 levels and disease risk) and reverse causation (e.g., reduced sun exposure and/or dietary absorption 9 due to the autoimmune disease) [3].

Adequately powered randomised control trials of vitamin D supplementation among people with
 autoimmune diseases are scarce. In the recent VITAL trial [4], vitamin D supplementation (2000
 IU/day over a median of 5.3 years) reduced risk of autoimmune diseases as a composite outcome

13 (hazard ratio 0.78, 95% confidence interval 0.61-0.99, P=0.05). However, uncertainties remain in

part due to a relatively small number of events (n=278 among 25,871 participants), possibly because

15 the mean age of the trial population (67 years) is older than the peak incidence age for some

16 autoimmune diseases. The trial was not powered to examine individual autoimmune diseases, which

17 is important since any biologic effects of vitamin D on the immune system is unlikely to be shared

across pathologically diverse conditions. VITAL was also not powered to examine whether risk

19 reduction differed according to baseline vitamin D, which is important to assess potential threshold

20 or non-linear effects of intervention.

21 Genetic instrumental variable designs, also known as Mendelian randomization (MR), can help with

22 these challenges. Since genetic variants are randomly allocated at conception, MR is typically more

robust against confounding and reverse causation compared to traditional observational designs.

24 Large population level genetic data can power subgroup analyses of pathologically related

25 conditions, while recent methodologic developments can help examine non-linear effects of vitamin

26 D interventions. We conducted both population-wide and stratified MR analyses to assess evidence

27 for potential causal effects of vitamin D on autoimmune diseases and to interrogate any non-

28 linearity in the relationship.

29

### 1 METHODS

#### 2 Study populations and outcomes

3 We performed population-wide and stratified Mendelian randomization analyses in the UK Biobank, a prospective cohort study of around 0.5 million participants aged 40 to 69 years at baseline, 4 recruited between 2006-2010 in the United Kingdom and followed-up for a median of 10.9 years [5]. 5 6 UK Biobank has approval from the North West Multi-centre Research Ethics Committee and all 7 participants provided written informed consent. The UK Biobank received ethical approval Analyses 8 were restricted to unrelated individuals of European ancestries who passed various guality control steps as previously described [6] and had a valid 25-hydroxycholecalciferol (25(OH)D) measurement. 9 10 We considered a predefined list of outcomes based on ICD-9 and -10 codes (from fields 41270, 11 40001 or 40002) and/or self-reported diagnosis (field 20002); the full list of conditions, sample size 12 and definitions are shown in **Supplementary Table 1**. The conditions were first studied as a composite of "all autoimmune diseases", excluding multiple sclerosis (MS) for which prior MR 13 14 studies have suggested a causal relationship with vitamin D [7]. We then broadly classified diseases 15 in two groups according to a proposed classification method based on shared pathology and clinical 16 phenotype [8]: 17 1) Disease driven by "autoimmunity" (i.e., aberrant dendritic and adaptive immune cell 18 responses leading to breaking of tolerance and immune reactivity towards native antigens 19 [8]): rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjögren's syndrome, 20 systemic sclerosis, Graves' disease, Hashimoto's thyroiditis, Coeliac disease, type 1 diabetes 21 mellitus, primary biliary cholangitis, autoimmune hepatitis, polymyalgia rheumatica (PMR), 22 giant cell arteritis (GCA), polyarteritis nodosa, Henoch-Schönlein purpura, granulomatosis 23 with polyangiitis, eosinophilic granulomatosis with polyangiitis, microscopic polyangiitis, 24 mixed connective tissue disease, antiphospholipid syndrome, dermatomyositis and 25 polymyositis. 26 2) Disease driven by "autoinflammation" (i.e., local factors at sites predisposed to disease lead 27 to innate immune cell activation with resultant target tissue damage [8]): ankylosing 28 spondylitis, psoriatic arthritis, psoriasis, Crohn's disease, ulcerative colitis, primary sclerosing 29 cholangitis, Behcet's disease, Takayasu arteritis and Kawasaki disease. 30 Where mechanisms were less clear, diseases that were male-predominant and/or associated with HLA-B genes were grouped into the "autoinflammation" group [9] and remainder to the 31 32 "autoimmunity" group. In sensitivity analyses, we limited analyses to diseases with >100 cases and

- 1 for which the mechanism is better characterised within this classification system (i.e., the first ten in
- 2 the autoimmunity group and first five in the autoinflammation group). It is possible for individuals to
- 3 have more than one disease that belong to both groups. In further sensitivity analyses, we also
- 4 investigated outcomes defined as those only with diseases in the autoimmunity or autoinflammation
- 5 group.
- 6 We then analysed individual disease that affected at least 100 participants, since it was unlikely that
- 7 smaller sample sizes would provide meaningfully powered analyses. We included participants with
- 8 multiple autoimmune diseases for analyses of individual diseases, since some diseases commonly co-
- 9 exist (e.g., ankylosing spondylitis and psoriasis).
- 10 For all analyses, controls comprised those without any of the above conditions or MS. We recognise
- 11 that the control group will include individuals with other, rarer autoimmune conditions, but both
- 12 absolute numbers and proportions are small.
- 13 We included MS as a positive control outcome [7], and osteoarthritis, which is not considered an
- 14 autoimmune disease, as a negative control outcome.

### 15 Vitamin D measurement and classification

- 16 Concentrations of 25(OH)D in blood were measured using the DiaSorin Liaison immunoassay
- analyser. Measurements were adjusted for month of blood draw to correspond to a measurement
- 18 taken in October by subtracting the mean 25(OH)D concentration for the month the measurement
- 19 was taken in and then adding the mean 25(OH)D concentration measurements taken in October.
- 20 October was chosen as the reference month as 25(OH)D concentrations were close to their average
- annual value in October (Supplementary Table 2).

## 22 Genetic variants

- 23 To minimize potential bias due to horizontal pleiotropy, we considered genetic variants from four
- gene regions previously shown to be strongly associated with 25(OH)D [10] and implicated in the
- transport, metabolism, and synthesis of vitamin D GC, DHCR7, CYP2R1, and CYP24A1. To maximize
- the variance explained by the genetic instrument, we created a weighted genetic score from 21
- 27 variants associated with 25(OH)D concentrations at each genetic locus selected using a stepwise
- 28 selection method (**Supplementary Table 3**). A prior study showed that this genetic risk score was not
- associated with potential risk factors for autoimmune diseases in UK Biobank, except for BMI,
- 30 although this association was small [10]. By contrast, a score using variants from across the genome-
- 31 wide score was strongly associated with other traits that may introduce bias from pleiotropy.

## 1 Statistical methods

2 Population-wide analyses were performed by calculating the ratio between the association of the

3 genetic score with the outcome and the association of the score with 25(OH)D concentrations. We

4 performed logistic regression to estimate the associations of the score with the outcomes adjusting

5 for age, sex, assessment centre and 10 genetic principal components of ancestry. MR estimates were

6 scaled to a 10 nmol/L increase in genetically predicted 25(OH)D level.

7 In non-linear stratified analyses, we divided participants into five quantiles using the doubly ranked

8 method [11]. We firstly divide the population into pre-strata based on the instrument level, and then

9 divide into final strata based on the exposure level within each pre-stratum. Use of the doubly-

10 ranked method is important for 25(OH)D as an exposure, as genetic associations with 25(OH)D levels

11 vary strongly in the population [12]. MR estimates were calculated within each stratum as in the

12 population-wide analyses, but using genetic associations estimated in each stratum of the

13 population in turn.

## 14 Supplementary analyses

15 Sample sizes for individual autoimmune diseases are typically smaller in the UK Biobank compared

16 to dedicated GWAS consortia, which may limit the power of one-sample MR. Where possible, we

17 sought to replicate suggestive causal associations (arbitrarily defined as p value<0.1) between

18 25(OH)D and individual diseases using two-sample MR. Outcome genetic data were taken from

19 GWAS of psoriasis (10,588 physician diagnosed cases and 22,806 controls) and SLE (5,201 physician

20 diagnosed cases and 9,066 controls). Where such GWAS data were not available, we attempted to

21 replicate using data from FinnGen Release 8 [13] for GCA (884 cases, 332,115 controls) and PMR

22 (3039 cases, 332,115 controls). Instruments were identified as genome-wide significant ( $p<5x10^{-8}$ )

and uncorrelated (r<sup>2</sup><0.01) variants within GC, DHCR7, CYP2R1, and CYP24A1 genes as above, taken

from a GWAS meta-analysis of 25(OH)D [14]. We used the inverse variance weighted method which

25 combines ratio estimates from each variant and, where possible, pleiotropy robust sensitivity

26 analyses (i.e., MR Egger and weighted median/mode methods).

27

### 28 **RESULTS**

29 Of 332,984 participants included for analysis, 23,089 had one or more autoimmune diseases. Their

30 mean age was 59 years and 59% were females. The mean 25(OH)D concentration was 49 nmol/L,

and similar in both autoimmune disease and control groups (**Table 1**). 12,774 had at least one

32 disease of the "autoimmunity" group, and 11,164 had at least one disease in the

"autoinflammation" group. There was a higher proportion of females in the autoimmunity than the
 autoinflammation group (69 vs 47%).

3 The genetic risk score explained 4.7% of the variance in 25(OH)D concentrations. There was some

4 evidence that genetically predicted 25(OH)D was associated with reduced risk of autoimmune

5 diseases overall, but confidence intervals included the null (OR 0.97 per 10 nmol/L increase in

6 25(OH)D; 95%Cl 0.94, 1.01, p=0.10). This association appears to be predominantly driven by diseases

7 in the autoinflammation group (OR 0.95; 95%Cl 0.91, 0.99; p=0.03) (Figure 1). Sensitivity analyses

8 showed similar results when restricted to ten autoimmunity and five autoinflammation diseases

9 with >100 cases and for which disease mechanism is better characterised. Results were also similar

10 after excluding individuals with diseases in both subgroups showed similar estimates.

11 When diseases (with n>100) were analysed individually, psoriasis (OR 0.91; 95%CI 0.85, 0.97;

12 p=0.005), GCA (OR 0.79; 95%Cl 0.64, 0.98; p=0.03), PMR (OR 1.12; 95%Cl 0.997, 1.25; p=0.06) and

13 SLE (OR 0.84; 95%Cl 0.69, 1.02; p=0.09) showed some evidence of association with 25(OH)D

14 concentration (Figure 2). Genetically predicted 25(OH)D was not associated with the negative

15 control, osteoarthritis, but was associated with lower risk of the positive control, MS.

16 There was statistical evidence for non-linear associations, albeit with limited biologic plausibility,

17 between genetically-predicted 25(OH)D and the autoinflammation subgroup in the second (OR 0.82;

18 95%Cl 0.68, 0.995; p=0.04) and fourth quantiles (OR 0.77; 95%Cl 0.63, 0.93; p=0.006), but not any

19 other quantiles (Supplementary Table 4).

20 For psoriasis, GCA, PMR and SLE, we attempted to replicate analyses using two-sample MR. 14

21 variants were used to instrument 25(OH)D. Genetically-predicted 25(OH)D was associated with

lower risk of psoriasis (OR 0.52 per unit increase in log-transformed 25(OH)D; 95% 0.28, 0.96;

p=0.04) and SLE (OR 0.61; 95%Cl 0.40, 0.93; p=0.02). Estimates were directionally concordant in

24 pleiotropy robust sensitivity analyses (**Supplementary Table 5**). Primary analysis results were not

25 replicated for GCA (OR 0.95; 95%CI 0.47, 1.90; p=0.88) or PMR (OR 0.97; 95%CI 0.71, 1.33; p=0.87).

26

### 27 **DISCUSSION**

28 In this one-sample Mendelian randomisation analysis, we found evidence of a causal link between

29 vitamin D levels and diseases characterised by autoinflammation (i.e., by innate immune dysfunction

30 at local sites), which was driven by the psoriasis as the most prevalent disease in this group. There

31 was no statistical evidence of association between vitamin D and diseases characterised by

32 autoimmunity (i.e., autoreactivity against native antigens predominantly due to adaptive immune

1 dysfunction), although SLE may be one exception. We found no strong evidence for a plausible non-

2 linear relationship between vitamin D and any outcome.

3 Vitamin D has been associated with numerous health outcomes in observational studies, which 4 could not be replicated in randomised controlled trials [15]. Much of the trial evidence came from 5 the landmark VITAL study, which found no difference between vitamin D supplement and placebo 6 groups for a multitude of outcomes such as cancer and cardiovascular disease events [16], heart 7 failure [17], atrial fibrillation [18], depression [19], body composition [20], falls [21], bone mineral 8 density [22], fractures [23], frailty [24], knee pain [25], and biomarkers of inflammation [26]. 9 However, the vitamin D group did have lower incidence of confirmed autoimmune diseases 10 compared to placebo, but estimates included the null when including additional cases of probable 11 autoimmune disease and/or excluding those with pre-randomisation autoimmune diseases [4]. Analyses of individual diseases (rheumatoid arthritis, polymyalgia rheumatica, psoriasis and a 12 13 composite of the remainder) were all underpowered. Younger individuals and those with vitamin D 14 deficiency (13%) were underrepresented. Taken together, VITAL provided long awaited randomised 15 evidence, but much uncertainty remained in the context of multiple testing and regarding disease-

16 specific or threshold effects.

17 Our results help to address these uncertainties. By leveraging much larger sample sizes of 18 autoimmune diseases across the age spectrum, we show that vitamin D's effect is likely to differ 19 across individual diseases. We found evidence supporting a causal link between 25(OH)D and 20 diseases characterised by autoinflammation but not autoimmunity. Genetic and clinical differences 21 between these disease subgroups have been described previously [8], and is evident from the 22 differential sex-predominance observed herein. The association with autoinflammatory diseases is 23 almost certainly driven by psoriatic disease. The estimate from VITAL was directionally concordant 24 but underpowered due to having only 38 psoriasis cases overall. We observed a similar association 25 for psoriatic arthritis but with a wide confidence interval. The biological rationale for psoriasis is 26 strong since topical vitamin D analogues are approved treatments. However, no high-quality trial 27 evidence exists for oral vitamin D supplementation in reducing psoriasis risk. Among the diseases 28 characterised by autoimmunity, SLE appears to be associated with vitamin D. This is consistent with 29 prior observational evidence [27], but the 5 cases of SLE in VITAL could not power formal analyses. 30 The associations between vitamin D and GCA and PMR should be interpreted with caution. Firstly, it 31 is less biologically plausible that vitamin D should have opposing effects on two related diseases. 32 Secondly, they were not replicated using the FinnGen data.

1 Taken together, our results suggest that vitamin D supplementation in those at risk of psoriasis or 2 SLE may help reduce disease susceptibility, with no evidence indicating a threshold level. These 3 results will also help inform future clinical trials that are needed to confirm our findings, for 4 example, enriching populations with those at risk of psoriasis or SLE but not necessarily with vitamin 5 D deficiency. The precise mechanism behind vitamin D's effect on psoriasis and SLE cannot be 6 derived from the current study. The VITAL trial found no benefit of vitamin D on IL6 or CRP [26] 7 which are not the dominant inflammatory pathways in either disease. Future clinical trials should 8 also focus on relevant mechanisms, e.g., involving T helper 17 and B cells. 9 The key strength of MR is that it is less susceptible to bias from confounding and reverse causation 10 than conventional observational analyses. We selected instruments from genes relevant to vitamin 11 D biology, which reduces potential bias from horizontal pleiotropy (i.e., arising from variants that do 12 not have specific effects on vitamin D pathways). However, this important assumption cannot be 13 empirically verified. Our use of biologically plausible variants may also explain why results differ 14 from previous studies that adopted mechanism-agnostic variant-selection [28]. Misclassification of 15 the outcome is possible when using diagnostic codes and self-report, which may increase risk of false 16 negatives, particularly when sample sizes are small. Multiple testing is also of concern when 17 considering individual diseases. However, we were able to replicate results for psoriasis and SLE 18 using GWAS data derived from independent data with physician diagnosed cases. MR estimates the 19 effect of subtle variations in lifelong exposure, thus results may not be comparable to therapeutic 20 interventions. Our study only included participants of European ancestry. Future studies among 21 other ethnic populations are needed to examine generalisability of the current findings, which is 22 particularly relevant as skin colour influences vitamin D metabolism. Lastly, our data includes both prevalent and incident events; therefore, stratification into categories according to residual 25(OH)D 23 24 concentration might be affected by reverse causation. However, genetic associations with disease 25 outcomes within each of the strata will not be affected by reverse causation, as genotype is fixed 26 from conception. 27 In conclusion, we found genetic evidence to support a causal link between 25(OH)D concentrations

and autoinflammatory diseases such as psoriasis. These results have implications for the

interpretation and design of vitamin D supplementation trials, and potential disease preventionstrategies.

31

## 32 Acknowledgements

- 1 We thank the participants of the UK Biobank study and the genome-wide association study consortia
- 2 who made their summary statistics publicly available for this study. This work was supported by core
- 3 funding from the: British Heart Foundation (RG/13/13/30194; RG/18/13/33946), BHF Cambridge
- 4 CRE (RE/18/1/34212) and NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The
- 5 views expressed are those of the author(s) and not necessarily those of the NIHR or the Department
- 6 of Health and Social Care.

# 7 Rights Retention Statement

- 8 For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY)
- 9 licence to any Author Accepted Manuscript version arising from this submission.
- 10 **Conflict of interest disclosures:** The authors declare no conflicts of interest.
- 11 Data Sharing Statement: UK Biobank data are available to all bona fide researchers for use in health-
- 12 related research that is in the public interest. The application procedure is described at
- 13 www.ukbiobank.ac.uk.
- 14 **Funding and disclosures**: SSZ is supported by a National Institute for Health Research (NIHR)
- 15 Academic Clinical Lectureship and works in centres supported by Versus Arthritis (grant number
- 16 21173, 21754 and 21755). A.M.M. is funded by the EU/EFPIA Innovative Medicines Initiative Joint
- 17 Undertaking BigData@Heart grant 116074. SB is supported by the Wellcome Trust (225790/Z/22/Z)
- 18 the United Kingdom Research and Innovation Medical Research Council (MC\_UU\_00002/7) and the
- 19 National Institute for Health Research Cambridge Biomedical Research Centre (NIHR203312). The
- 20 views expressed are those of the authors and not necessarily those of the National Health Service,
- 21 the National Institute for Health Research, or the Department of Health and Social Care.

# 22 Author contributions

All authors – SZ, AM, EG, HY, SB – have made substantial contributions to all of the following: (1) the conception and design of the study, or acquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectual content, (3) final approval of the version to be submitted. SZ takes responsibility for the integrity of the work as a whole, from inception to finished article.

28

1	Table 1.	Characteristics of	of autoimmune	disease grou	up and subgroups
---	----------	--------------------	---------------	--------------	------------------

	All autoimmune	Autoimmunity	Autoinflammation	Controls
	diseases	subgroup	subgroup	
Ν	23089	12774	11164	308521
Age, years	58.7 (7.8)	59.7 (7.4)	57.6 (7.9)	57.0 (8.1)
Females	13584 (58.8)	8853 (69.3)	5269 (47.2)	163153 (52.9)
BMI	27.8 (5.1)	27.7 (5.3)	27.9 (5.0)	27.3 (4.7)
Vitamin D, nmol/L	49.3 (21.7)	50.0 (22.0)	48.5 (21.4)	49.4 (20.8)
Rheumatoid arthritis	5172 (46.3)	5172 (40.5)	436 (3.9)	0
Systemic lupus	527 (4.7)	527 (4.1)	36 (0.3)	0
erythematosus				
Systemic sclerosis	201 (1.8)	201 (1.6)	11 (0.1)	0
Sjögren's syndrome	335 (3)	335 (2.6)	23 (0.2)	0
Graves' disease	1798 (16.1)	1798 (14.1)	85 (0.8)	0
Hashim ot o' s	194 (1.7)	194 (1.5)	6 (0.1)	0
thyroiditis				
Coeliac disease	2249 (20.1)	2249 (17.6)	125 (1.1)	0
Type 1 diabetes	341 (3.1)	341 (2.7)	12 (0.1)	0
mellitus				
Primary biliary	243 (2.2)	243 (1.9)	35 (0.3)	0
cholangitis				
Autoimmune	153 (1.4)	153 (1.2)	19 (0.2)	
hepatitis				
Polymyalgia	1780 (15.9)	1780 (13.9)	90 (0.8)	0
rheumatica				_
Giant cell arteritis	436 (3.9)	436 (3.4)	20 (0.2)	0
polyarteritis nodosa	91 (0.8)	91 (0.7)	10 (0.1)	0
Granulomatosis with	62 (0.6)	62 (0.5)	7 (0.1)	0
polyangiitis		47 (0.4)	7 (0 1)	0
Henoch-Schonlein	47 (0.4)	47 (0.4)	7 (0.1)	0
purpura Eosinophilis	46 (0 4)	46 (0 4)	7 (0 1)	0
Granulomatosis with	40 (0.4)	40 (0.4)	7 (0.1)	0
nolvangiitis				
Mixed connective	41 (0 4)	41 (0 3)	4 (0.04)	0
tissue disease	41 (0.4)	41 (0.0)	- (0.0-7)	Ū
Antiphospholipid	28 (0.3)	28 (0.2)	2 (0.02)	0
syndrome	()	()	- ()	-
, Microscopic	19 (0.2)	19 (0.1)	1 (0.01)	0
polyangiitis	х <i>У</i>	, , , , , , , , , , , , , , , , , , ,	· · · ·	
Dermato/polymyositis	6 (0.1)	6 (0.05)	0	0
Ankylosing spondylitis	1121 (10.0)	111 (0.9)	1121 (10.0)	0
Psoriatic arthritis	703 (6.3)	89 (0.7)	703 (6.3)	0
Crohn's disease	1795 (16.1)	162 (1.3)	1795 (16.1)	0
Ulcerative colitis	3461 (31.0)	278 (2.2)	3461 (31.0)	0
Psoriasis	, 5120 (45.9)	335 (2.6)	, 5120 (45.9)	0
Primary sclerosing	35 (0.3)	16 (0.1) 16 (0.1)	35 (0.3)	0
cholangitis	()	()	()	-
Behçet <sup>'</sup> s disease	30 (0.3)	7 (0.1)	30 (0.3)	0

Takayasu arteritis	6 (0.1)	1 (0.01)	6 (0.1)	0
Kawasaki disease	1 (0.01)	1 (0.01)	1 (0.01)	0

1

2 Values represent mean (standard deviation) for continuous traits, and number of cases (percentage

3 of total cases) for binary traits and disease outcomes. Autoimmune diseases were separated into

4 those characterised by autoimmunity (i.e., aberrant dendritic and adaptive immune cell responses

5 leading to breaking of tolerance and immune reactivity towards native antigens) and

6 autoinflammation subgroups (i.e., local factors at sites predisposed to disease lead to innate

7 immune cell activation with resultant target tissue damage).

- 1 **Figure 1.** Association between genetically predicted vitamin D concentration and autoimmune
- 2 diseases, including autoimmunity and autoinflammatory subgroups.

	OR	95%CI	p-value
Primary analysis All autoimmune diseases Autoimmunity Autoinflammation	 0.97 0.99 0.95	[0.94; 1.01] [0.95; 1.03] [0.91; 0.99]	0.10 0.64 0.03
Sensitivity analysis Autoimmunity n>100 Autoinflammation n>100 Autoimmunity only Autoinflammation only	0.98 0.95 1.00 0.95	[0.94; 1.03] [0.91; 0.99] [0.95; 1.04] [0.91; 1.00]	0.49 0.03 0.88 0.05

3

- 4 Legend: Individuals in the primary analysis could have diseases in both autoimmunity (i.e., aberrant
- 5 dendritic and adaptive immune cell responses leading to breaking of tolerance and immune
- 6 reactivity towards native antigens) and autoinflammation subgroups (i.e., local factors at sites
- 7 predisposed to disease lead to innate immune cell activation with resultant target tissue damage).

8 The first set of sensitivity analyses were restricted to diseases with >100 cases for which disease

- 9 mechanisms are better understood. In the second set of sensitive analyses, individuals with disease
- 10 belong to both groups were excluded.

OR

95%CI p-value

- 1 Figure 2. Associations between genetically predicted vitamin D concentration and individual
- 2 autoimmune diseases.

Autoimmunity Rheumatoid arthritis Systemic lupus erythematosus Systemic sclerosis Sjogren's syndrome Graves disease Hashimoto's thyroiditis		0.97 [0.91; 1.03] 0.84 [0.69; 1.02] 	0.30 0.08 0.50 0.89 0.80 0.82
Type 1 diabetes mellitus Autoimmune hepatitis Primary biliary cholangitis Polymyalgia rheumatica Giant cell arteritis		1.02 [0.83; 1.19] 1.08 [0.83; 1.39] 0.96 [0.66; 1.39] 	0.57 0.82 0.36 0.06 0.03
Autoinflammation Ankylosing spondylitis Crohn's disease Ulcerative colitis Psoriatic arthritis Psoriasis		0.97 [0.85; 1.12] 0.98 [0.88; 1.10] 0.96 [0.89; 1.04] 0.92 [0.78; 1.10] 0.91 [0.85; 0.97]	0.71 0.73 0.37 0.37 < 0.01
Negative control Osteoarthritis	-	0.99 [0.96; 1.02]	0.58
Positive control Multiple sclerosis	0.75 1	0.82 [0.73; 0.92] 1.5	< 0.01

3

# 1 **REFERENCES**

- Conrad N, Verbeke G, Molenberghs G, Goetschalckx L, Callender T, Cambridge G, et al.
  Autoimmune diseases and cardiovascular risk: a population-based study on 19 autoimmune
  diseases and 12 cardiovascular diseases in 22 million individuals in the UK. Lancet
  2022;400:733–43.
- Hayter SM, Cook MC. Updated assessment of the prevalence, spectrum and case definition of
  autoimmune disease. Autoimmun Rev 2012;11:754–65.
- Kriegel MA, Manson JE, Costenbader KH. Does vitamin D affect risk of developing autoimmune
  disease?: a systematic review. Semin Arthritis Rheum 2011;40:512-531.e8.
- Hahn J, Cook NR, Alexander EK, Friedman S, Walter J, Bubes V, et al. Vitamin D and marine
  omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized
  controlled trial. BMJ 2022;376:e066452.
- 135.Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank resource14with deep phenotyping and genomic data. Nature 2018;562:203–9.
- Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, et al. The Allelic Landscape of Human
  Blood Cell Trait Variation and Links to Common Complex Disease. Cell 2016;167:1415 1429.e19.
- Mokry LE, Ross S, Ahmad OS, Forgetta V, Smith GD, Goltzman D, et al. Vitamin D and Risk of
  Multiple Sclerosis: A Mendelian Randomization Study. PLoS Med 2015;12:e1001866.
- 8. McGonagle D, McDermott MF. A Proposed Classification of the Immunological Diseases. PLOS
  Medicine 2006;3:e297.
- McGonagle D, Aydin SZ, Gül A, Mahr A, Direskeneli H. 'MHC-l-opathy'-unified concept for
  spondyloarthritis and Behçet disease. Nat Rev Rheumatol 2015;11:731–40.
- Sofianopoulou E, Kaptoge SK, Afzal S, Jiang T, Gill D, Gundersen TE, et al. Estimating doseresponse relationships for vitamin D with coronary heart disease, stroke, and all-cause mortality: observational and Mendelian randomisation analyses. The Lancet Diabetes & Endocrinology 2021;9:837–46.
- Tian H, Mason AM, Liu C, Burgess S. Relaxing parametric assumptions for non-linear Mendelian
  randomization using a doubly-ranked stratification method [Internet]. 2022 [cited 2023 Feb
  23];2022.06.28.497930. Available from:
- 31 https://www.biorxiv.org/content/10.1101/2022.06.28.497930v1
- Burgess S. Violation of the constant genetic effect assumption can result in biased estimates
  for non-linear Mendelian randomization [Internet]. 2022 [cited 2023 Feb
- 34 23];2022.10.26.22280570. Available from:
- 35 https://www.medrxiv.org/content/10.1101/2022.10.26.22280570v1
- 36 13. Access results [Internet]. FinnGen [cited 2023 Feb 23];Available from:
- 37 https://www.finngen.fi/en/access\_results
- Revez JA, Lin T, Qiao Z, Xue A, Holtz Y, Zhu Z, et al. Genome-wide association study identifies
  143 loci associated with 25 hydroxyvitamin D concentration. Nat Commun 2020;11:1647.

1 15. Lucas A, Wolf M. Vitamin D and Health Outcomes: Then Came the Randomized Clinical Trials. 2 JAMA 2019;322:1866-8. 3 16. Manson JE, Cook NR, Lee IM, Christen W, Bassuk SS, Mora S, et al. Vitamin D Supplements and 4 Prevention of Cancer and Cardiovascular Disease. New England Journal of Medicine 5 2019;380:33-44. 6 17. Djoussé L, Cook NR, Kim E, Bodar V, Walter J, Bubes V, et al. Supplementation With Vitamin D 7 and Omega-3 Fatty Acids and Incidence of Heart Failure Hospitalization. Circulation 8 2020;141:784-6. 9 Albert CM, Cook NR, Pester J, Moorthy MV, Ridge C, Danik JS, et al. Effect of Marine Omega-3 18. 10 Fatty Acid and Vitamin D Supplementation on Incident Atrial Fibrillation: A Randomized Clinical 11 Trial. JAMA 2021;325:1061-73. 12 19. Okereke OI, Reynolds CF III, Mischoulon D, Chang G, Vyas CM, Cook NR, et al. Effect of Long-13 term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant 14 Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. JAMA 15 2020;324:471-80. 16 20. Chou SH, Murata EM, Yu C, Danik J, Kotler G, Cook NR, et al. Effects of Vitamin D3 17 Supplementation on Body Composition in the VITamin D and OmegA-3 TriaL (VITAL). J Clin 18 Endocrinol Metab 2021;106:1377-88. 19 LeBoff MS, Murata EM, Cook NR, Cawthon P, Chou SH, Kotler G, et al. VITamin D and OmegA-3 21. 20 TriaL (VITAL): Effects of Vitamin D Supplements on Risk of Falls in the US Population. The 21 Journal of Clinical Endocrinology & Metabolism 2020;105:2929-38. 22 22. LeBoff MS, Chou SH, Murata EM, Donlon CM, Cook NR, Mora S, et al. Effects of Supplemental 23 Vitamin D on Bone Health Outcomes in Women and Men in the VITamin D and OmegA-3 TriaL 24 (VITAL). J Bone Miner Res 2020;35:883-93. 25 23. LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, et al. Supplemental Vitamin D and 26 Incident Fractures in Midlife and Older Adults. New England Journal of Medicine 27 2022;387:299-309. 28 24. Orkaby AR, Dushkes R, Ward R, Djousse L, Buring JE, Lee IM, et al. Effect of Vitamin D3 and 29 Omega-3 Fatty Acid Supplementation on Risk of Frailty: An Ancillary Study of a Randomized 30 Clinical Trial. JAMA Netw Open 2022;5:e2231206. 31 25. MacFarlane LA, Cook NR, Kim E, Lee IM, Iversen MD, Gordon D, et al. The Effects of Vitamin D 32 and Marine Omega-3 Fatty Acid Supplementation on Chronic Knee Pain in Older US Adults: 33 Results From a Randomized Trial. Arthritis Rheumatol 2020;72:1836-44. 34 26. Costenbader KH, MacFarlane LA, Lee IM, Buring JE, Mora S, Bubes V, et al. Effects of One Year 35 of Vitamin D and Marine Omega-3 Fatty Acid Supplementation on Biomarkers of Systemic 36 Inflammation in Older US Adults. Clin Chem 2019;65:1508–21. 37 Shoenfeld Y, Giacomelli R, Azrielant S, Berardicurti O, Reynolds JA, Bruce IN. Vitamin D and 27. 38 systemic lupus erythematosus - The hype and the hope. Autoimmunity Reviews 2018;17:19-39 23.

- 1 28. Bae SC, Lee YH. Vitamin D level and risk of systemic lupus erythematosus and rheumatoid
- 2 arthritis: a Mendelian randomization. Clin Rheumatol 2018;37:2415–21.